Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab

Diffuse Large B Cell Lymphoma Clinical Trial

Official title:

Retrospective Observational Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab: a Subanalysis of the RTXM83-AC-01-11 Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04928573
• Other study ID #: LB2002
• Status: Completed
• Start date: February 8, 2022
• Est. completion date: March 23, 2023

Study information

• Verified date: July 2022
• Source: Libbs Farmacêutica LTDA
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The RTXM83-AC-01-11 study evaluated efficacy and safety outcomes in relation to the use of Vivaxxia during 6 treatment cycles (at the investigator's discretion, up to 8 treatment cycles could be administered), followed by 9 months of follow-up. , this follow-up time being sufficient for the analysis of non-inferiority in relation to the reference medicine. However, data on late events of efficacy and safety are of great value to contribute to a robust clinical response and to strengthen confidence in the use of biosimilar medicines. For this reason, Libbs Farmacêutica proposes this retrospective observational study to collect data on late outcomes of the pivotal study that directed the approval of the biosimilar rituximab (Vivaxxia) from the research participants from Brazil.

The present retrospective observational study LB2002 will sub-analyze selected results of efficacy and safety from study RTXM83-AC-01-11 in participants over 18 years of age randomized in Brazil, totaling 28 participants, in addition to evaluating late efficacy and safety outcomes. Information on subsequent treatment / protocol should also be collected for participants who have progressive or recurrent disease, instituted by research centers under these conditions.

The proposal is to compare descriptively the selected outcomes of efficacy and safety of these participants with the same outcomes selected for the global population in the RTXM83-AC-01-11 study, and also provide late safety and effective data important for anti-neoplastic processes.

Description:

Evaluate research participants who were refractory to treatment, defined as not having achieved: Complete Response (CR) or Partial Response (PR), after 6 treatment cycles in study RTXM83-AC-01-11.

Evaluate the participants who had a recurrence of the disease, defined as a change from:

Complete Response (CR), after 06 treatment cycles in study RTXM83-AC-01-11, to: Progressive Disease (PD) until the date of consent (ICF) in the LB2002 study.

The data of the subsequent treatment / protocol instituted by the research center for progressive or recurrent disease will also be collected.

PERIOD OF ANALYSIS OF THIS CLINICAL STUDY

• 01-JUL-2013 (beginning of the study) to 17-JUL-2017 (data in which the last participant of the study RTXM83-AC-01-11 arrived at the last follow-up visit at 9 months after the last dose of treatment): for sub-analysis of efficacy and safety proposed by study RTXM83-AC-01-11: SLE, TRG and EA, and for exploratory evaluation of refractory disease.

• Data from randomization in study RTXM83-AC-01-11 to consent data (TCLE) in study LB2002:

for analysis of SLP, SG and for exploratory evaluation of relapse.

• Date of the final visit of study RTXM83-AC-01-11, considered as FUP3, until the date of consent (ICF) in study LB2002: for the evaluation of late AEs of interest.

Data collect:For the subanalysis evaluations, the data that have already been collected will be used and are part of the study database RTXM83-AC-01-11. This database will also be considered for exploratory assessment of refractory disease.

For late evaluations of safety and efficacy (late adverse events of interest, SLP, SG and disease recurrence) and also data on the subsequent treatment / protocol instituted by the research center for progressive disease or disease recurrence, data from medical records available at research centers.

Finally, all the data necessary to evaluate the objectives established in this study will be imputed in a single Electronic Case Report Form (eCRF) developed exclusively for this project.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 23, 2023
• Est. primary completion date: July 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Free and informed consent to participate in this retrospective, observational study of data collection

• Research participants from Brazil randomized and who received at least one dose of treatment in the RTXM83-AC-01-11 study.

Exclusion Criteria:

• not applicable

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Locations

Country	Name	City	State
Brazil	Dr Fernando Pericole	Campinas	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Libbs Farmacêutica LTDA

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness evaluation: subanalysis of event-free survival	To present the subanalysis of event-free survival of participants from Brazil in the two treatment groups (RTXM83-CHOP and R-CHOP) from the randomization date until the final visit of the RTXM83-AC-01-11 study, considered as o FUP 3 (9-month follow-up after the end of treatment);	9 months after treatment
Primary	Effectiveness evaluation: subanalysis of the Global Response Rate	To present the subanalysis of the Global Response Rate of participants from Brazil in the two treatment groups (RTXM83-CHOP and R-CHOP), after 6 treatment cycles in the RTXM83-AC-01-11 study, assessed as Complete Response ( RC) or Partial Response (PR);	At the end of Cycle 6 (each cycle is 03 weeks)
Primary	Security evaluation: sub-analysis of the adverse events	Present the sub-analysis of the adverse events (AE) of the participants in Brazil that occurred from the date of signing the Free and Informed Consent Form (ICF) until the final visit of the study RTXM83-AC-01-11, considered as the FUP 3 (follow-up) 9 months after the end of treatment);	9 months after treatment
Primary	Effectiveness evaluation: progression-free survival	Assess progression-free survival in the two treatment groups (RTXM83-CHOP and R-CHOP) from the date of randomization in the RTXM83-AC-01-11 study until the date of consent (ICF) in the LB2002 study;	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months
Primary	Effectiveness evaluation: Assess the overall survival	Assess the overall survival in the two treatment groups (RTXM83-CHOP and R-CHOP) from the date of randomization in study RTXM83-AC-01-11 until the date of consent (ICF) in study LB2002;	From date of randomization until the date of death from any cause, assessed up to 96 months
Primary	Security evaluation: occurrence of late adverse events	Evaluate the occurrence of late adverse events of interest from the date of the final visit of the RTXM83-AC-01-11 study, considered as FUP 3, until the date of consent (TCLE) in the LB2002 study.	From date of randomization until the date of death from any cause, assessed up to 96 months